GCAR, Eisai and UPMC, on Behalf of REMAP-CAP Investigator Network, Announce Eritoran’s Inclusion in REMAP-COVID, An Adaptive Clinical Trial to Test Interventions for Patients With Moderate and Severe ...
It’s unlikely that adding an antiplatelet agent to anticoagulation will increase the number of organ support-free days in critically ill patients with COVID-19, although it’s possible that survival in ...
CHESTERBROOK, Pa., April 21, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with ...
NovaBiotics' NM002 (cysteamine bitartrate) Under Investigation in a Phase 3 Study for Community Acquired Pneumonia, Including COVID-19, Influenzas and Bacterial Pneumonias REMAP-CAP is a global ...
PERTH, Australia – Melbourne, Australia-based Dimerix Ltd. saw its shares gain 66% on the news that its lead candidate, DMX-200, has been chosen to enter the global REMAP-CAP platform trial as a ...
The world’s largest trial of multiple interventions for critically ill adults with COVID-19 has simultaneously released results about two of its treatments, vitamin C and simvastatin LARKSPUR, Calif. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback